Principal Financial Group
INO icon

Principal Financial Group’s Inovio Pharmaceuticals INO Stock Holding History

Principal Financial Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,696
Closed -$34.9K – 2458
2023
Q4 		$34.9K Buy
5,696
+585
+11% +$2.89K ﹤0.01% 2355
2023
Q3 		$23.9K Hold
5,111
– – ﹤0.01% 2400
2023
Q2 		$27.4K Sell
5,111
-651
-11% -$5.25K ﹤0.01% 2400
2023
Q1 		$56.7K Buy
5,762
+785
+16% +$13.4K ﹤0.01% 2363
2022
Q4 		$93.2K Buy
4,977
+849
+21% +$19.2K ﹤0.01% 2303
2022
Q3 		$85K Buy
4,128
+1,208
+41% +$30.9K ﹤0.01% 2358
2022
Q2 		$61K Sell
2,920
-446
-13% -$12.6K ﹤0.01% 2447
2022
Q1 		$145K Sell
3,366
-234
-7% -$10.5K ﹤0.01% 2387
2021
Q4 		$216K Sell
3,600
-1,277
-26% -$102K ﹤0.01% 2338
2021
Q3 		$419K Sell
4,877
-1,089
-18% -$109K ﹤0.01% 2220
2021
Q2 		$663K Sell
5,966
-428
-7% -$41.1K ﹤0.01% 2144
2021
Q1 		$712K Buy
6,394
+142
+2% +$18.7K ﹤0.01% 2064
2020
Q4 		$664K Buy
6,252
+2,546
+69% +$339K ﹤0.01% 2037
2020
Q3 		$515K Sell
3,706
-92
-2% -$19.2K ﹤0.01% 2019
2020
Q2 		$1.23M Buy
3,798
+2,803
+282% +$450K ﹤0.01% 1789
2020
Q1 		$89K Sell
995
-100
-9% -$6.17K ﹤0.01% 2124
2019
Q4 		$43K Sell
1,095
-1,304
-54% -$39.2K ﹤0.01% 2214
2019
Q3 		$59K Buy
2,399
+221
+10% +$6.72K ﹤0.01% 2207
2019
Q2 		$77K Buy
2,178
+137
+7% +$5.44K ﹤0.01% 2194
2019
Q1 		$92K Buy
2,041
+28
+1% +$1.41K ﹤0.01% 2159
2018
Q4 		$97K Sell
2,013
-422
-17% -$25.6K ﹤0.01% 2178
2018
Q3 		$162K Buy
2,435
+299
+14% +$16.6K ﹤0.01% 2194
2018
Q2 		$100K Sell
2,136
-121
-5% -$6.67K ﹤0.01% 2224
2018
Q1 		$127K Sell
2,257
-36
-2% -$1.95K ﹤0.01% 2142
2017
Q4 		$114K Buy
2,293
+1,422
+163% +$88.1K ﹤0.01% 2177
2017
Q3 		$66K Sell
871
-163
-16% -$12.1K ﹤0.01% 2158
2017
Q2 		$97K Sell
1,034
-2,733
-73% -$234K ﹤0.01% 2189
2017
Q1 		$300K Hold
3,767
– – ﹤0.01% 2011
2016
Q4 		$313K Buy
3,767
+2,777
+281% +$251K ﹤0.01% 2003
2016
Q3 		$111K Buy
990
+17
+2% +$1.88K ﹤0.01% 2094
2016
Q2 		$108K Sell
973
-72
-7% -$8.75K ﹤0.01% 2082
2016
Q1 		$109K Buy
1,045
+30
+3% +$2.32K ﹤0.01% 2078
2015
Q4 		$82K Hold
1,015
– – ﹤0.01% 2120
2015
Q3 		$70K Sell
1,015
-620
-38% -$54K ﹤0.01% 2113
2015
Q2 		$160K Buy
1,635
+352
+27% +$37.6K ﹤0.01% 2077
2015
Q1 		$126K Sell
1,283
-16
-1% -$1.55K ﹤0.01% 2080
2014
Q4 		$143K Buy
+1,299
New +$159K ﹤0.01% 2078
2014
Q3 		– Sell
-1,460
Closed -$189K – 2225
2014
Q2 		$189K Buy
+1,460
New +$172K ﹤0.01% 2101

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Principal Financial Group's INO Position: Q1 2024 in Review

Principal Financial Group sold out of Inovio Pharmaceuticals (INO) in Q1 2024, closing a stake of 5,696 shares — an estimated $34.9K sold.

Principal Financial Group first reported a position in INO in Q2 2014 and held it in 38 quarters. The position peaked at $1.23M in Q2 2020. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.

  • Principal Financial Group reported no remaining Inovio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Principal Financial Group sold 5,696 Inovio Pharmaceuticals shares in Q1 2024, an estimated $34.9K.
  • Principal Financial Group first reported a position in Inovio Pharmaceuticals in Q2 2014 and held it in 38 quarters.
  • Principal Financial Group's Inovio Pharmaceuticals position peaked at $1.23M in Q2 2020.
  • 89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.

Based on Principal Financial Group's 13F filing for Q1 2024, filed 29 Apr 2024.